Altered T-cell reactivity in the early stages of Alzheimer's disease - Takeaways - MDSpire

Altered T-cell reactivity in the early stages of Alzheimer's disease

  • By

  • Chiara Rickenbach

  • Anna Mallone

  • Lars Häusle

  • Larissa Frei

  • Sarina Seiter

  • Colin Sparano

  • Tunahan Kirabali

  • Kaj Blennow

  • Henrik Zetterberg

  • Maria Teresa Ferretti

  • Luka Kulic

  • Christoph Hock

  • Roger M Nitsch

  • Valerie Treyer

  • Anton Gietl

  • Christoph Gericke

  • May 5, 2025

  • 0 min

Share

  • 1

    The study investigates T-cell responses in early stages of Alzheimer's disease (AD), focusing on preclinical AD and mild cognitive impairment (MCI).

  • 2

    CD4+ T cells in preclinical AD show a type 2 T-helper profile and reactivity against amyloid-β peptides, suggesting a potentially beneficial role.

  • 3

    In MCI, there is an increased frequency of CD8+ T effector memory cells with a pro-inflammatory gene expression profile, indicating potential harm.

  • 4

    The research employs advanced techniques like mass cytometry and single-cell RNA sequencing to analyze immune cell populations in blood and CSF.

  • 5

    Findings suggest that promoting specific CD4+ T-cell responses in preclinical AD may be beneficial, while targeting CD8+ T-cell responses in MCI may be necessary.

Original Source(s)

Altered T-cell reactivity in the early stages of Alzheimer's disease

  • by Chiara Rickenbach, Anna Mallone, Lars Häusle, Larissa Frei, Sarina Seiter, Colin Sparano, Tunahan Kirabali, Kaj Blennow, Henrik Zetterberg, Maria Teresa Ferretti, Luka Kulic, Christoph Hock, Roger M Nitsch, Valerie Treyer, Anton Gietl, Christoph Gericke

  • May 5, 2025

Related Content

High-Level Alzheimer Disease Neuropathological Change Following Iatrogenic Exposure

Association between neurodegenerative plasma biomarkers and geriatric depression in older adults with and without clinical dementia in Kinshasa, Democratic Republic of the Congo

Association between circulating biomarkers of one-carbon metabolism and glymphatic system function in cognitive decline of Alzheimer’s disease